nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—Spinal Cord Injury—NOX4—atherosclerosis	0.0115	0.0336	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—CX3CR1—atherosclerosis	0.00916	0.0269	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—HRH1—atherosclerosis	0.00706	0.0207	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—PLA2G2A—atherosclerosis	0.0069	0.0202	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—SELP—atherosclerosis	0.0069	0.0202	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—EDNRA—atherosclerosis	0.00662	0.0194	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—CCR2—atherosclerosis	0.00662	0.0194	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRH1—atherosclerosis	0.00632	0.0185	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—AGTR1—atherosclerosis	0.00563	0.0165	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCL4—atherosclerosis	0.00504	0.0148	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HSPD1—atherosclerosis	0.00495	0.0145	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—HRH1—atherosclerosis	0.00468	0.0137	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CCR2—atherosclerosis	0.00456	0.0134	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—UTS2—atherosclerosis	0.00455	0.0134	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—UTS2—atherosclerosis	0.00449	0.0132	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—CASR—atherosclerosis	0.00436	0.0128	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CX3CR1—atherosclerosis	0.00431	0.0126	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CX3CL1—atherosclerosis	0.00423	0.0124	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—UTS2—atherosclerosis	0.00407	0.0119	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—CASR—atherosclerosis	0.0039	0.0115	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—HRH1—atherosclerosis	0.00356	0.0105	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCL3—atherosclerosis	0.00344	0.0101	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL4—atherosclerosis	0.00338	0.00993	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—ESR2—atherosclerosis	0.00337	0.00988	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDNRA—atherosclerosis	0.00316	0.00926	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDNRA—atherosclerosis	0.00312	0.00914	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCR2—atherosclerosis	0.00312	0.00914	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GHRL—atherosclerosis	0.00308	0.00902	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—GHRL—atherosclerosis	0.00304	0.00891	CbGpPWpGaD
Fosaprepitant—Muscular weakness—Niacin—atherosclerosis	0.00303	0.00459	CcSEcCtD
Fosaprepitant—Infestation NOS—Ezetimibe—atherosclerosis	0.00302	0.00458	CcSEcCtD
Fosaprepitant—Infestation—Ezetimibe—atherosclerosis	0.00302	0.00458	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—UTS2—atherosclerosis	0.00301	0.00885	CbGpPWpGaD
Fosaprepitant—Urinary tract infection—Lovastatin—atherosclerosis	0.00299	0.00454	CcSEcCtD
Fosaprepitant—Abdominal distension—Niacin—atherosclerosis	0.00299	0.00453	CcSEcCtD
Fosaprepitant—Muscular weakness—Pravastatin—atherosclerosis	0.00298	0.00452	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00298	0.00452	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Simvastatin—atherosclerosis	0.00295	0.00447	CcSEcCtD
Fosaprepitant—Abdominal distension—Pravastatin—atherosclerosis	0.00294	0.00446	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CX3CR1—atherosclerosis	0.00289	0.00848	CbGpPWpGaD
Fosaprepitant—Mental disorder—Rosuvastatin—atherosclerosis	0.00286	0.00434	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.00286	0.00433	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CX3CL1—atherosclerosis	0.00283	0.00832	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—atherosclerosis	0.00282	0.00828	CbGpPWpGaD
Fosaprepitant—Flatulence—Rosuvastatin—atherosclerosis	0.0028	0.00425	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—atherosclerosis	0.00275	0.00807	CbGpPWpGaD
Fosaprepitant—Dysuria—Pravastatin—atherosclerosis	0.00273	0.00414	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—KNG1—atherosclerosis	0.0027	0.00792	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.00269	0.00789	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—AGTR1—atherosclerosis	0.00268	0.00787	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—LEP—atherosclerosis	0.00267	0.00785	CbGpPWpGaD
Fosaprepitant—Photosensitivity reaction—Pravastatin—atherosclerosis	0.00267	0.00405	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00267	0.00404	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—KNG1—atherosclerosis	0.00266	0.00782	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGTR1—atherosclerosis	0.00265	0.00777	CbGpPWpGaD
Fosaprepitant—Weight decreased—Pravastatin—atherosclerosis	0.00264	0.00401	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TLR4—atherosclerosis	0.00262	0.00769	CbGpPWpGaD
Fosaprepitant—Erythema multiforme—Lovastatin—atherosclerosis	0.00261	0.00397	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL10—atherosclerosis	0.0026	0.00763	CbGpPWpGaD
Fosaprepitant—Angioedema—Rosuvastatin—atherosclerosis	0.0026	0.00394	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.00258	0.00392	CcSEcCtD
Fosaprepitant—Stomatitis—Niacin—atherosclerosis	0.00258	0.00391	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CCL4—atherosclerosis	0.00258	0.00756	CbGpPWpGaD
Fosaprepitant—Flushing—Lovastatin—atherosclerosis	0.00257	0.00389	CcSEcCtD
Fosaprepitant—Erythema multiforme—Ezetimibe—atherosclerosis	0.00256	0.00389	CcSEcCtD
Fosaprepitant—Urinary tract infection—Pravastatin—atherosclerosis	0.00253	0.00384	CcSEcCtD
Fosaprepitant—Flushing—Ezetimibe—atherosclerosis	0.00252	0.00382	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—ICAM1—atherosclerosis	0.00251	0.00737	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—NOS2—atherosclerosis	0.00249	0.00731	CbGpPWpGaD
Fosaprepitant—Cough—Rosuvastatin—atherosclerosis	0.00248	0.00376	CcSEcCtD
Fosaprepitant—Angiopathy—Ezetimibe—atherosclerosis	0.00246	0.00373	CcSEcCtD
Fosaprepitant—Immune system disorder—Ezetimibe—atherosclerosis	0.00245	0.00372	CcSEcCtD
Fosaprepitant—Erythema multiforme—Simvastatin—atherosclerosis	0.00245	0.00371	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00244	0.00371	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—atherosclerosis	0.00241	0.00708	CbGpPWpGaD
Fosaprepitant—Flushing—Simvastatin—atherosclerosis	0.0024	0.00364	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—atherosclerosis	0.0024	0.00704	CbGpPWpGaD
Fosaprepitant—Mental disorder—Ezetimibe—atherosclerosis	0.00238	0.0036	CcSEcCtD
Fosaprepitant—Flatulence—Lovastatin—atherosclerosis	0.00237	0.0036	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Niacin—atherosclerosis	0.00236	0.00359	CcSEcCtD
Fosaprepitant—Erythema—Ezetimibe—atherosclerosis	0.00236	0.00358	CcSEcCtD
Fosaprepitant—Malnutrition—Ezetimibe—atherosclerosis	0.00236	0.00358	CcSEcCtD
Fosaprepitant—Dysgeusia—Lovastatin—atherosclerosis	0.00236	0.00358	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Pravastatin—atherosclerosis	0.00233	0.00353	CcSEcCtD
Fosaprepitant—Flatulence—Ezetimibe—atherosclerosis	0.00233	0.00353	CcSEcCtD
Fosaprepitant—Muscle spasms—Lovastatin—atherosclerosis	0.00231	0.00351	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.00231	0.00678	CbGpPWpGaD
Fosaprepitant—Infection—Rosuvastatin—atherosclerosis	0.0023	0.00349	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—UTS2—atherosclerosis	0.0023	0.00674	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDN1—atherosclerosis	0.00227	0.00667	CbGpPWpGaD
Fosaprepitant—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00227	0.00345	CcSEcCtD
Fosaprepitant—Muscle spasms—Ezetimibe—atherosclerosis	0.00227	0.00344	CcSEcCtD
Fosaprepitant—Mental disorder—Simvastatin—atherosclerosis	0.00227	0.00344	CcSEcCtD
Fosaprepitant—Erythema—Simvastatin—atherosclerosis	0.00225	0.00342	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CCL2—atherosclerosis	0.00225	0.00659	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDN1—atherosclerosis	0.00225	0.00659	CbGpPWpGaD
Fosaprepitant—Ill-defined disorder—Lovastatin—atherosclerosis	0.00223	0.00339	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCL5—atherosclerosis	0.00223	0.00654	CbGpPWpGaD
Fosaprepitant—Eye disorder—Niacin—atherosclerosis	0.00222	0.00337	CcSEcCtD
Fosaprepitant—Flatulence—Simvastatin—atherosclerosis	0.00222	0.00337	CcSEcCtD
Fosaprepitant—Tinnitus—Niacin—atherosclerosis	0.00221	0.00336	CcSEcCtD
Fosaprepitant—Erythema multiforme—Pravastatin—atherosclerosis	0.00221	0.00335	CcSEcCtD
Fosaprepitant—Dysgeusia—Simvastatin—atherosclerosis	0.00221	0.00335	CcSEcCtD
Fosaprepitant—Flushing—Niacin—atherosclerosis	0.0022	0.00334	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CX3CR1—atherosclerosis	0.0022	0.00646	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CASR—atherosclerosis	0.0022	0.00646	CbGpPWpGaD
Fosaprepitant—Angioedema—Lovastatin—atherosclerosis	0.0022	0.00334	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00219	0.00332	CcSEcCtD
Fosaprepitant—Anaemia—Ezetimibe—atherosclerosis	0.00218	0.00331	CcSEcCtD
Fosaprepitant—Tinnitus—Pravastatin—atherosclerosis	0.00218	0.00331	CcSEcCtD
Fosaprepitant—Malaise—Lovastatin—atherosclerosis	0.00217	0.00329	CcSEcCtD
Fosaprepitant—Cardiac disorder—Pravastatin—atherosclerosis	0.00217	0.00329	CcSEcCtD
Fosaprepitant—Flushing—Pravastatin—atherosclerosis	0.00217	0.00329	CcSEcCtD
Fosaprepitant—Muscle spasms—Simvastatin—atherosclerosis	0.00216	0.00328	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CX3CL1—atherosclerosis	0.00216	0.00633	CbGpPWpGaD
Fosaprepitant—Angioedema—Ezetimibe—atherosclerosis	0.00216	0.00327	CcSEcCtD
Fosaprepitant—Angiopathy—Niacin—atherosclerosis	0.00215	0.00327	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—atherosclerosis	0.00214	0.00628	CbGpPWpGaD
Fosaprepitant—Malaise—Ezetimibe—atherosclerosis	0.00213	0.00323	CcSEcCtD
Fosaprepitant—Insomnia—Rosuvastatin—atherosclerosis	0.0021	0.00318	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.00209	0.00613	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.00209	0.00613	CbGpPWpGaD
Fosaprepitant—Ill-defined disorder—Simvastatin—atherosclerosis	0.00209	0.00317	CcSEcCtD
Fosaprepitant—Palpitations—Ezetimibe—atherosclerosis	0.00209	0.00317	CcSEcCtD
Fosaprepitant—Anaemia—Simvastatin—atherosclerosis	0.00208	0.00316	CcSEcCtD
Fosaprepitant—Malnutrition—Niacin—atherosclerosis	0.00207	0.00314	CcSEcCtD
Fosaprepitant—Erythema—Niacin—atherosclerosis	0.00207	0.00314	CcSEcCtD
Fosaprepitant—Cough—Ezetimibe—atherosclerosis	0.00206	0.00313	CcSEcCtD
Fosaprepitant—Angioedema—Simvastatin—atherosclerosis	0.00206	0.00312	CcSEcCtD
Fosaprepitant—Chest pain—Lovastatin—atherosclerosis	0.00205	0.00311	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CNR2—atherosclerosis	0.00205	0.006	CbGpPWpGaD
Fosaprepitant—Anxiety—Lovastatin—atherosclerosis	0.00204	0.0031	CcSEcCtD
Fosaprepitant—Dyspepsia—Rosuvastatin—atherosclerosis	0.00204	0.0031	CcSEcCtD
Fosaprepitant—Hypertension—Ezetimibe—atherosclerosis	0.00204	0.00309	CcSEcCtD
Fosaprepitant—Flatulence—Niacin—atherosclerosis	0.00204	0.00309	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.00204	0.00598	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—atherosclerosis	0.00203	0.00597	CbGpPWpGaD
Fosaprepitant—Malaise—Simvastatin—atherosclerosis	0.00203	0.00308	CcSEcCtD
Fosaprepitant—Discomfort—Lovastatin—atherosclerosis	0.00203	0.00307	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—HRH1—atherosclerosis	0.00201	0.00591	CbGpPWpGaD
Fosaprepitant—Chest pain—Ezetimibe—atherosclerosis	0.00201	0.00305	CcSEcCtD
Fosaprepitant—Flatulence—Pravastatin—atherosclerosis	0.00201	0.00304	CcSEcCtD
Fosaprepitant—Dry mouth—Lovastatin—atherosclerosis	0.002	0.00304	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.002	0.00303	CcSEcCtD
Fosaprepitant—Dysgeusia—Pravastatin—atherosclerosis	0.00199	0.00302	CcSEcCtD
Fosaprepitant—Muscle spasms—Niacin—atherosclerosis	0.00199	0.00302	CcSEcCtD
Fosaprepitant—Discomfort—Ezetimibe—atherosclerosis	0.00199	0.00301	CcSEcCtD
Fosaprepitant—Pain—Rosuvastatin—atherosclerosis	0.00198	0.00301	CcSEcCtD
Fosaprepitant—Constipation—Rosuvastatin—atherosclerosis	0.00198	0.00301	CcSEcCtD
Fosaprepitant—Dry mouth—Ezetimibe—atherosclerosis	0.00197	0.00298	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Lovastatin—atherosclerosis	0.00196	0.00298	CcSEcCtD
Fosaprepitant—Muscle spasms—Pravastatin—atherosclerosis	0.00196	0.00297	CcSEcCtD
Fosaprepitant—Infection—Lovastatin—atherosclerosis	0.00195	0.00296	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00193	0.00292	CcSEcCtD
Fosaprepitant—Chest pain—Simvastatin—atherosclerosis	0.00192	0.00291	CcSEcCtD
Fosaprepitant—Infection—Ezetimibe—atherosclerosis	0.00191	0.0029	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IFNG—atherosclerosis	0.00191	0.00561	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00191	0.0029	CcSEcCtD
Fosaprepitant—Anxiety—Simvastatin—atherosclerosis	0.00191	0.0029	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.0019	0.00288	CcSEcCtD
Fosaprepitant—Discomfort—Simvastatin—atherosclerosis	0.00189	0.00287	CcSEcCtD
Fosaprepitant—Nervous system disorder—Ezetimibe—atherosclerosis	0.00189	0.00287	CcSEcCtD
Fosaprepitant—Angioedema—Niacin—atherosclerosis	0.00189	0.00287	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Pravastatin—atherosclerosis	0.00189	0.00287	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—AGT—atherosclerosis	0.00189	0.00554	CbGpPWpGaD
Fosaprepitant—Anaemia—Pravastatin—atherosclerosis	0.00188	0.00285	CcSEcCtD
Fosaprepitant—Skin disorder—Ezetimibe—atherosclerosis	0.00187	0.00284	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGT—atherosclerosis	0.00186	0.00547	CbGpPWpGaD
Fosaprepitant—Angioedema—Pravastatin—atherosclerosis	0.00186	0.00282	CcSEcCtD
Fosaprepitant—Syncope—Niacin—atherosclerosis	0.00185	0.00281	CcSEcCtD
Fosaprepitant—Urticaria—Rosuvastatin—atherosclerosis	0.00184	0.00279	CcSEcCtD
Fosaprepitant—Oedema—Simvastatin—atherosclerosis	0.00184	0.00279	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Simvastatin—atherosclerosis	0.00184	0.00279	CcSEcCtD
Fosaprepitant—Malaise—Pravastatin—atherosclerosis	0.00184	0.00278	CcSEcCtD
Fosaprepitant—Abdominal pain—Rosuvastatin—atherosclerosis	0.00183	0.00278	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—PTGS2—atherosclerosis	0.00183	0.00538	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HRH1—atherosclerosis	0.00183	0.00537	CbGpPWpGaD
Fosaprepitant—Palpitations—Niacin—atherosclerosis	0.00183	0.00277	CcSEcCtD
Fosaprepitant—Infection—Simvastatin—atherosclerosis	0.00183	0.00277	CcSEcCtD
Fosaprepitant—Loss of consciousness—Niacin—atherosclerosis	0.00182	0.00276	CcSEcCtD
Fosaprepitant—Cough—Niacin—atherosclerosis	0.0018	0.00274	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.00179	0.00525	CbGpPWpGaD
Fosaprepitant—Insomnia—Lovastatin—atherosclerosis	0.00178	0.0027	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.00178	0.00521	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL8—atherosclerosis	0.00178	0.00521	CbGpPWpGaD
Fosaprepitant—Cough—Pravastatin—atherosclerosis	0.00178	0.00269	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CCL3—atherosclerosis	0.00176	0.00516	CbGpPWpGaD
Fosaprepitant—Hypertension—Pravastatin—atherosclerosis	0.00176	0.00267	CcSEcCtD
Fosaprepitant—Dyspnoea—Lovastatin—atherosclerosis	0.00175	0.00266	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00175	0.00265	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—F2—atherosclerosis	0.00174	0.00512	CbGpPWpGaD
Fosaprepitant—Insomnia—Ezetimibe—atherosclerosis	0.00174	0.00264	CcSEcCtD
Fosaprepitant—Chest pain—Pravastatin—atherosclerosis	0.00173	0.00263	CcSEcCtD
Fosaprepitant—Dyspepsia—Lovastatin—atherosclerosis	0.00173	0.00262	CcSEcCtD
Fosaprepitant—Anxiety—Pravastatin—atherosclerosis	0.00173	0.00262	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—F2—atherosclerosis	0.00172	0.00505	CbGpPWpGaD
Fosaprepitant—Dry mouth—Niacin—atherosclerosis	0.00172	0.00261	CcSEcCtD
Fosaprepitant—Dyspnoea—Ezetimibe—atherosclerosis	0.00172	0.00261	CcSEcCtD
Fosaprepitant—Discomfort—Pravastatin—atherosclerosis	0.00171	0.0026	CcSEcCtD
Fosaprepitant—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00171	0.00259	CcSEcCtD
Fosaprepitant—Decreased appetite—Lovastatin—atherosclerosis	0.00171	0.00259	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL1B—atherosclerosis	0.0017	0.005	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Ezetimibe—atherosclerosis	0.0017	0.00257	CcSEcCtD
Fosaprepitant—Fatigue—Lovastatin—atherosclerosis	0.00169	0.00257	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	0.00169	0.00495	CbGpPWpGaD
Fosaprepitant—Oedema—Niacin—atherosclerosis	0.00169	0.00256	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Niacin—atherosclerosis	0.00169	0.00256	CcSEcCtD
Fosaprepitant—Constipation—Lovastatin—atherosclerosis	0.00168	0.00255	CcSEcCtD
Fosaprepitant—Pain—Lovastatin—atherosclerosis	0.00168	0.00255	CcSEcCtD
Fosaprepitant—Decreased appetite—Ezetimibe—atherosclerosis	0.00168	0.00254	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00166	0.00252	CcSEcCtD
Fosaprepitant—Asthenia—Rosuvastatin—atherosclerosis	0.00166	0.00252	CcSEcCtD
Fosaprepitant—Insomnia—Simvastatin—atherosclerosis	0.00166	0.00252	CcSEcCtD
Fosaprepitant—Oedema—Pravastatin—atherosclerosis	0.00166	0.00252	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Pravastatin—atherosclerosis	0.00166	0.00252	CcSEcCtD
Fosaprepitant—Fatigue—Ezetimibe—atherosclerosis	0.00166	0.00252	CcSEcCtD
Fosaprepitant—Shock—Niacin—atherosclerosis	0.00166	0.00252	CcSEcCtD
Fosaprepitant—Infection—Pravastatin—atherosclerosis	0.00165	0.0025	CcSEcCtD
Fosaprepitant—Constipation—Ezetimibe—atherosclerosis	0.00165	0.0025	CcSEcCtD
Fosaprepitant—Pain—Ezetimibe—atherosclerosis	0.00165	0.0025	CcSEcCtD
Fosaprepitant—Pruritus—Rosuvastatin—atherosclerosis	0.00164	0.00249	CcSEcCtD
Fosaprepitant—Skin disorder—Niacin—atherosclerosis	0.00164	0.00249	CcSEcCtD
Fosaprepitant—Dyspnoea—Simvastatin—atherosclerosis	0.00164	0.00249	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Niacin—atherosclerosis	0.00163	0.00247	CcSEcCtD
Fosaprepitant—Feeling abnormal—Lovastatin—atherosclerosis	0.00162	0.00246	CcSEcCtD
Fosaprepitant—Dyspepsia—Simvastatin—atherosclerosis	0.00162	0.00245	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—atherosclerosis	0.00161	0.00472	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00161	0.00244	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Pravastatin—atherosclerosis	0.00161	0.00244	CcSEcCtD
Fosaprepitant—Decreased appetite—Simvastatin—atherosclerosis	0.0016	0.00242	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—EDNRA—atherosclerosis	0.00159	0.00467	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCR2—atherosclerosis	0.00159	0.00467	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Ezetimibe—atherosclerosis	0.00159	0.00241	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00159	0.00241	CcSEcCtD
Fosaprepitant—Diarrhoea—Rosuvastatin—atherosclerosis	0.00159	0.00241	CcSEcCtD
Fosaprepitant—Fatigue—Simvastatin—atherosclerosis	0.00158	0.0024	CcSEcCtD
Fosaprepitant—Hypotension—Niacin—atherosclerosis	0.00158	0.00239	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00158	0.00239	CcSEcCtD
Fosaprepitant—Constipation—Simvastatin—atherosclerosis	0.00157	0.00238	CcSEcCtD
Fosaprepitant—Pain—Simvastatin—atherosclerosis	0.00157	0.00238	CcSEcCtD
Fosaprepitant—Urticaria—Lovastatin—atherosclerosis	0.00156	0.00237	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	0.00156	0.00458	CbGpPWpGaD
Fosaprepitant—Body temperature increased—Lovastatin—atherosclerosis	0.00155	0.00236	CcSEcCtD
Fosaprepitant—Abdominal pain—Lovastatin—atherosclerosis	0.00155	0.00236	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—GHRL—atherosclerosis	0.00155	0.00455	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCL2—atherosclerosis	0.00154	0.0045	CbGpPWpGaD
Fosaprepitant—Dizziness—Rosuvastatin—atherosclerosis	0.00153	0.00233	CcSEcCtD
Fosaprepitant—Urticaria—Ezetimibe—atherosclerosis	0.00153	0.00232	CcSEcCtD
Fosaprepitant—Insomnia—Niacin—atherosclerosis	0.00153	0.00232	CcSEcCtD
Fosaprepitant—Abdominal pain—Ezetimibe—atherosclerosis	0.00152	0.00231	CcSEcCtD
Fosaprepitant—Body temperature increased—Ezetimibe—atherosclerosis	0.00152	0.00231	CcSEcCtD
Fosaprepitant—Feeling abnormal—Simvastatin—atherosclerosis	0.00151	0.0023	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.00151	0.00442	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Niacin—atherosclerosis	0.0015	0.00228	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Simvastatin—atherosclerosis	0.0015	0.00228	CcSEcCtD
Fosaprepitant—Insomnia—Pravastatin—atherosclerosis	0.0015	0.00228	CcSEcCtD
Fosaprepitant—Somnolence—Niacin—atherosclerosis	0.0015	0.00228	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.00149	0.00439	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Niacin—atherosclerosis	0.00149	0.00225	CcSEcCtD
Fosaprepitant—Dyspnoea—Pravastatin—atherosclerosis	0.00148	0.00225	CcSEcCtD
Fosaprepitant—Decreased appetite—Niacin—atherosclerosis	0.00147	0.00223	CcSEcCtD
Fosaprepitant—Dyspepsia—Pravastatin—atherosclerosis	0.00146	0.00222	CcSEcCtD
Fosaprepitant—Rash—Rosuvastatin—atherosclerosis	0.00146	0.00222	CcSEcCtD
Fosaprepitant—Dermatitis—Rosuvastatin—atherosclerosis	0.00146	0.00222	CcSEcCtD
Fosaprepitant—Urticaria—Simvastatin—atherosclerosis	0.00146	0.00221	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Niacin—atherosclerosis	0.00146	0.00221	CcSEcCtD
Fosaprepitant—Body temperature increased—Simvastatin—atherosclerosis	0.00145	0.0022	CcSEcCtD
Fosaprepitant—Abdominal pain—Simvastatin—atherosclerosis	0.00145	0.0022	CcSEcCtD
Fosaprepitant—Headache—Rosuvastatin—atherosclerosis	0.00145	0.0022	CcSEcCtD
Fosaprepitant—Hypersensitivity—Lovastatin—atherosclerosis	0.00145	0.0022	CcSEcCtD
Fosaprepitant—Decreased appetite—Pravastatin—atherosclerosis	0.00144	0.00219	CcSEcCtD
Fosaprepitant—Pain—Niacin—atherosclerosis	0.00144	0.00219	CcSEcCtD
Fosaprepitant—Fatigue—Pravastatin—atherosclerosis	0.00143	0.00217	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—atherosclerosis	0.00142	0.00417	CbGpPWpGaD
Fosaprepitant—Constipation—Pravastatin—atherosclerosis	0.00142	0.00216	CcSEcCtD
Fosaprepitant—Pain—Pravastatin—atherosclerosis	0.00142	0.00216	CcSEcCtD
Fosaprepitant—Hypersensitivity—Ezetimibe—atherosclerosis	0.00142	0.00215	CcSEcCtD
Fosaprepitant—Asthenia—Lovastatin—atherosclerosis	0.00141	0.00214	CcSEcCtD
Fosaprepitant—Pruritus—Lovastatin—atherosclerosis	0.00139	0.00211	CcSEcCtD
Fosaprepitant—Asthenia—Ezetimibe—atherosclerosis	0.00138	0.0021	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Niacin—atherosclerosis	0.00138	0.00209	CcSEcCtD
Fosaprepitant—Nausea—Rosuvastatin—atherosclerosis	0.00138	0.00209	CcSEcCtD
Fosaprepitant—Feeling abnormal—Pravastatin—atherosclerosis	0.00137	0.00208	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MAPK3—atherosclerosis	0.00137	0.00401	CbGpPWpGaD
Fosaprepitant—Pruritus—Ezetimibe—atherosclerosis	0.00136	0.00207	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—atherosclerosis	0.00136	0.004	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—KNG1—atherosclerosis	0.00136	0.00399	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00136	0.00206	CcSEcCtD
Fosaprepitant—Hypersensitivity—Simvastatin—atherosclerosis	0.00135	0.00205	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—AGTR1—atherosclerosis	0.00135	0.00397	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Lovastatin—atherosclerosis	0.00134	0.00204	CcSEcCtD
Fosaprepitant—Urticaria—Niacin—atherosclerosis	0.00134	0.00203	CcSEcCtD
Fosaprepitant—Body temperature increased—Niacin—atherosclerosis	0.00133	0.00202	CcSEcCtD
Fosaprepitant—Abdominal pain—Niacin—atherosclerosis	0.00133	0.00202	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TGFB1—atherosclerosis	0.00132	0.00389	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCL4—atherosclerosis	0.00132	0.00388	CbGpPWpGaD
Fosaprepitant—Urticaria—Pravastatin—atherosclerosis	0.00132	0.002	CcSEcCtD
Fosaprepitant—Asthenia—Simvastatin—atherosclerosis	0.00132	0.002	CcSEcCtD
Fosaprepitant—Diarrhoea—Ezetimibe—atherosclerosis	0.00132	0.002	CcSEcCtD
Fosaprepitant—Abdominal pain—Pravastatin—atherosclerosis	0.00131	0.00199	CcSEcCtD
Fosaprepitant—Body temperature increased—Pravastatin—atherosclerosis	0.00131	0.00199	CcSEcCtD
Fosaprepitant—Pruritus—Simvastatin—atherosclerosis	0.0013	0.00197	CcSEcCtD
Fosaprepitant—Dizziness—Lovastatin—atherosclerosis	0.0013	0.00197	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—UTS2—atherosclerosis	0.0013	0.00381	CbGpPWpGaD
Fosaprepitant—Dizziness—Ezetimibe—atherosclerosis	0.00127	0.00193	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—NFKB1—atherosclerosis	0.00127	0.00373	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Simvastatin—atherosclerosis	0.00126	0.00191	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.00125	0.00367	CbGpPWpGaD
Fosaprepitant—Vomiting—Lovastatin—atherosclerosis	0.00125	0.0019	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CASR—atherosclerosis	0.00124	0.00365	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Niacin—atherosclerosis	0.00124	0.00189	CcSEcCtD
Fosaprepitant—Rash—Lovastatin—atherosclerosis	0.00124	0.00188	CcSEcCtD
Fosaprepitant—Dermatitis—Lovastatin—atherosclerosis	0.00124	0.00188	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—atherosclerosis	0.00124	0.00363	CbGpPWpGaD
Fosaprepitant—Headache—Lovastatin—atherosclerosis	0.00123	0.00187	CcSEcCtD
Fosaprepitant—Vomiting—Ezetimibe—atherosclerosis	0.00123	0.00186	CcSEcCtD
Fosaprepitant—Hypersensitivity—Pravastatin—atherosclerosis	0.00122	0.00186	CcSEcCtD
Fosaprepitant—Dizziness—Simvastatin—atherosclerosis	0.00122	0.00184	CcSEcCtD
Fosaprepitant—Rash—Ezetimibe—atherosclerosis	0.00122	0.00184	CcSEcCtD
Fosaprepitant—Dermatitis—Ezetimibe—atherosclerosis	0.00121	0.00184	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—atherosclerosis	0.00121	0.00356	CbGpPWpGaD
Fosaprepitant—Asthenia—Niacin—atherosclerosis	0.00121	0.00184	CcSEcCtD
Fosaprepitant—Headache—Ezetimibe—atherosclerosis	0.00121	0.00183	CcSEcCtD
Fosaprepitant—Pruritus—Niacin—atherosclerosis	0.00119	0.00181	CcSEcCtD
Fosaprepitant—Asthenia—Pravastatin—atherosclerosis	0.00119	0.00181	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—UTS2—atherosclerosis	0.00118	0.00346	CbGpPWpGaD
Fosaprepitant—Pruritus—Pravastatin—atherosclerosis	0.00118	0.00178	CcSEcCtD
Fosaprepitant—Vomiting—Simvastatin—atherosclerosis	0.00117	0.00177	CcSEcCtD
Fosaprepitant—Nausea—Lovastatin—atherosclerosis	0.00117	0.00177	CcSEcCtD
Fosaprepitant—Rash—Simvastatin—atherosclerosis	0.00116	0.00176	CcSEcCtD
Fosaprepitant—Dermatitis—Simvastatin—atherosclerosis	0.00116	0.00176	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CNR2—atherosclerosis	0.00116	0.00339	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.00116	0.00339	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Niacin—atherosclerosis	0.00115	0.00175	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—atherosclerosis	0.00115	0.00339	CbGpPWpGaD
Fosaprepitant—Headache—Simvastatin—atherosclerosis	0.00115	0.00175	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—EDN1—atherosclerosis	0.00115	0.00337	CbGpPWpGaD
Fosaprepitant—Nausea—Ezetimibe—atherosclerosis	0.00114	0.00174	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CCL5—atherosclerosis	0.00114	0.00334	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Pravastatin—atherosclerosis	0.00114	0.00172	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CASR—atherosclerosis	0.00113	0.00331	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CX3CR1—atherosclerosis	0.00113	0.00331	CbGpPWpGaD
Fosaprepitant—Dizziness—Niacin—atherosclerosis	0.00112	0.00169	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CX3CL1—atherosclerosis	0.00111	0.00325	CbGpPWpGaD
Fosaprepitant—Dizziness—Pravastatin—atherosclerosis	0.0011	0.00167	CcSEcCtD
Fosaprepitant—Nausea—Simvastatin—atherosclerosis	0.00109	0.00166	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HRH1—atherosclerosis	0.00108	0.00317	CbGpPWpGaD
Fosaprepitant—Vomiting—Niacin—atherosclerosis	0.00107	0.00163	CcSEcCtD
Fosaprepitant—Rash—Niacin—atherosclerosis	0.00106	0.00161	CcSEcCtD
Fosaprepitant—Dermatitis—Niacin—atherosclerosis	0.00106	0.00161	CcSEcCtD
Fosaprepitant—Headache—Niacin—atherosclerosis	0.00106	0.0016	CcSEcCtD
Fosaprepitant—Vomiting—Pravastatin—atherosclerosis	0.00106	0.0016	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CNR2—atherosclerosis	0.00105	0.00308	CbGpPWpGaD
Fosaprepitant—Rash—Pravastatin—atherosclerosis	0.00105	0.00159	CcSEcCtD
Fosaprepitant—Dermatitis—Pravastatin—atherosclerosis	0.00105	0.00159	CcSEcCtD
Fosaprepitant—Headache—Pravastatin—atherosclerosis	0.00104	0.00158	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.00103	0.00302	CbGpPWpGaD
Fosaprepitant—Nausea—Niacin—atherosclerosis	0.001	0.00152	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—atherosclerosis	0.000998	0.00293	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—atherosclerosis	0.000989	0.0029	CbGpPWpGaD
Fosaprepitant—Nausea—Pravastatin—atherosclerosis	0.000987	0.0015	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—AGT—atherosclerosis	0.000952	0.00279	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCL3—atherosclerosis	0.000903	0.00265	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCR2—atherosclerosis	0.000899	0.00264	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—EDNRA—atherosclerosis	0.000899	0.00264	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—F2—atherosclerosis	0.00088	0.00258	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GHRL—atherosclerosis	0.000876	0.00257	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOA4—atherosclerosis	0.000848	0.00249	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	0.000845	0.00248	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCR2—atherosclerosis	0.000817	0.0024	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EDNRA—atherosclerosis	0.000817	0.0024	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000814	0.00239	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—atherosclerosis	0.000798	0.00234	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GHRL—atherosclerosis	0.000796	0.00234	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCL2—atherosclerosis	0.000784	0.0023	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL4—atherosclerosis	0.000781	0.00229	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—KNG1—atherosclerosis	0.000769	0.00226	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGTR1—atherosclerosis	0.000765	0.00224	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOA2—atherosclerosis	0.00073	0.00214	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—KNG1—atherosclerosis	0.000699	0.00205	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—UTS2—atherosclerosis	0.000696	0.00204	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGTR1—atherosclerosis	0.000694	0.00204	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CX3CR1—atherosclerosis	0.000667	0.00196	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CASR—atherosclerosis	0.000667	0.00196	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CX3CL1—atherosclerosis	0.000654	0.00192	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—EDN1—atherosclerosis	0.000648	0.0019	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCL5—atherosclerosis	0.000643	0.00189	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CNR2—atherosclerosis	0.00062	0.00182	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL8—atherosclerosis	0.00062	0.00182	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MMP3—atherosclerosis	0.000619	0.00182	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	0.000618	0.00181	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PRKCG—atherosclerosis	0.000612	0.00179	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EDN1—atherosclerosis	0.000589	0.00173	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCL5—atherosclerosis	0.000584	0.00171	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PRKCG—atherosclerosis	0.000555	0.00163	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VWF—atherosclerosis	0.000553	0.00162	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOC3—atherosclerosis	0.00055	0.00161	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LDLR—atherosclerosis	0.000546	0.0016	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGT—atherosclerosis	0.000538	0.00158	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL3—atherosclerosis	0.000533	0.00157	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NCF1—atherosclerosis	0.000511	0.0015	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—F2—atherosclerosis	0.000497	0.00146	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGT—atherosclerosis	0.000489	0.00143	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCR2—atherosclerosis	0.000482	0.00142	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDNRA—atherosclerosis	0.000482	0.00142	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CYBA—atherosclerosis	0.00048	0.00141	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000476	0.0014	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLAT—atherosclerosis	0.00047	0.00138	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PARP1—atherosclerosis	0.00047	0.00138	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GHRL—atherosclerosis	0.00047	0.00138	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—F2—atherosclerosis	0.000452	0.00132	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CG—atherosclerosis	0.000432	0.00127	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KNG1—atherosclerosis	0.000413	0.00121	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGTR1—atherosclerosis	0.00041	0.0012	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCL2—atherosclerosis	0.000402	0.00118	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLG—atherosclerosis	0.0004	0.00117	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SOCS3—atherosclerosis	0.000379	0.00111	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP3—atherosclerosis	0.000366	0.00107	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF2—atherosclerosis	0.000364	0.00107	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOB—atherosclerosis	0.000353	0.00104	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL8—atherosclerosis	0.00035	0.00103	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDN1—atherosclerosis	0.000348	0.00102	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL5—atherosclerosis	0.000345	0.00101	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LPL—atherosclerosis	0.000337	0.00099	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKCG—atherosclerosis	0.000328	0.000963	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SPP1—atherosclerosis	0.00032	0.000938	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL8—atherosclerosis	0.000318	0.000934	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDGFB—atherosclerosis	0.000296	0.000868	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGT—atherosclerosis	0.000289	0.000847	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOE—atherosclerosis	0.000283	0.00083	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LEP—atherosclerosis	0.000283	0.00083	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CAV1—atherosclerosis	0.00028	0.000822	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOA1—atherosclerosis	0.00028	0.00082	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ESR1—atherosclerosis	0.00027	0.000792	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—F2—atherosclerosis	0.000267	0.000783	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CG—atherosclerosis	0.000255	0.000749	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MAPK3—atherosclerosis	0.000244	0.000717	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—INS—atherosclerosis	0.000242	0.000709	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL2—atherosclerosis	0.000238	0.000698	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF1—atherosclerosis	0.000234	0.000686	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SERPINE1—atherosclerosis	0.000222	0.000651	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOS3—atherosclerosis	0.000212	0.000622	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL8—atherosclerosis	0.000188	0.000552	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT1—atherosclerosis	0.000182	0.000533	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—atherosclerosis	0.000179	0.000524	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—atherosclerosis	0.00017	0.000499	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NFKB1—atherosclerosis	0.000168	0.000494	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK8—atherosclerosis	0.000165	0.000485	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT1—atherosclerosis	0.000165	0.000484	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—atherosclerosis	0.000153	0.000448	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT3—atherosclerosis	0.000151	0.000444	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK3—atherosclerosis	0.000144	0.000424	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFB1—atherosclerosis	0.00014	0.000411	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—atherosclerosis	0.000106	0.00031	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT1—atherosclerosis	9.74e-05	0.000286	CbGpPWpGaD
